PortalPublikationenPrognostic impact of progression to induction chemotherapy a...

Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party

Standard

Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. / Necchi, A; Miceli, R; Bregni, M; Bokemeyer, C; Berger, L A; Oechsle, K; Schumacher, K; Kanfer, E; Bourhis, J H; Massard, C; Laszlo, D; Montoro, J; Flechon, A; Arpaci, F; Secondino, S; Wuchter, P; Dreger, P; Crysandt, M; Worel, N; Kruger, W; Ringhoffer, M; Unal, A; Nagler, A; Campos, A; Wahlin, A; Michieli, M; Sucak, G; Donnini, I; Schots, R; Ifrah, N; Badoglio, M; Martino, M; Raggi, D; Giannatempo, P; Rosti, G; Pedrazzoli, P; Lanza, F.

in: BONE MARROW TRANSPL, Jahrgang 51, Nr. 3, 03.2016, S. 384-90.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Necchi, A, Miceli, R, Bregni, M, Bokemeyer, C, Berger, LA, Oechsle, K, Schumacher, K, Kanfer, E, Bourhis, JH, Massard, C, Laszlo, D, Montoro, J, Flechon, A, Arpaci, F, Secondino, S, Wuchter, P, Dreger, P, Crysandt, M, Worel, N, Kruger, W, Ringhoffer, M, Unal, A, Nagler, A, Campos, A, Wahlin, A, Michieli, M, Sucak, G, Donnini, I, Schots, R, Ifrah, N, Badoglio, M, Martino, M, Raggi, D, Giannatempo, P, Rosti, G, Pedrazzoli, P & Lanza, F 2016, 'Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party', BONE MARROW TRANSPL, Jg. 51, Nr. 3, S. 384-90. https://doi.org/10.1038/bmt.2015.300

APA

Necchi, A., Miceli, R., Bregni, M., Bokemeyer, C., Berger, L. A., Oechsle, K., Schumacher, K., Kanfer, E., Bourhis, J. H., Massard, C., Laszlo, D., Montoro, J., Flechon, A., Arpaci, F., Secondino, S., Wuchter, P., Dreger, P., Crysandt, M., Worel, N., ... Lanza, F. (2016). Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. BONE MARROW TRANSPL, 51(3), 384-90. https://doi.org/10.1038/bmt.2015.300

Vancouver

Necchi A, Miceli R, Bregni M, Bokemeyer C, Berger LA, Oechsle K et al. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. BONE MARROW TRANSPL. 2016 Mär;51(3):384-90. https://doi.org/10.1038/bmt.2015.300

Bibtex

@article{8332e3b4b11440fd8058cdd05ae756e2,
title = "Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party",
abstract = "Little is known about the prognostic impact of prior paclitaxel therapy and response to induction chemotherapy defined as the regimen preceding high-dose chemotherapy (HDCT) for the salvage therapy of advanced germ cell tumors. Twenty European Society for Blood and Marrow Transplantation centers contributed data on patients treated between 2002 and 2012. Paclitaxel used in either prior lines of therapy or in induction-mobilization regimens was considered. Multivariable Cox analyses of prespecified factors were undertaken on PFS and overall survival (OS). As of October 2013, data for 324 patients had been contributed to this study. One hundred and ninety-two patients (59.3%) had received paclitaxel. Sixty-one patients (19%) had a progression to induction chemotherapy, 234 (72%) a response (29 (9%) missing or granulocyte colony-stimulating factor without chemotherapy). Both progression to induction chemotherapy and prior paclitaxel were significantly associated with shorter OS univariably (P<0.001 and P=0.032). On multivariable analysis from the model with fully available data (N=216) progression to induction was significantly prognostic for PFS and OS (P=0.003), but prior paclitaxel was not (P=0.674 and P=0.739). These results were confirmed after multiple imputation of missing data. Progression to induction chemotherapy could be demonstrated as an independent prognostic factor, in contrast to prior paclitaxel.Bone Marrow Transplantation advance online publication, 7 December 2015; doi:10.1038/bmt.2015.300.",
author = "A Necchi and R Miceli and M Bregni and C Bokemeyer and Berger, {L A} and K Oechsle and K Schumacher and E Kanfer and Bourhis, {J H} and C Massard and D Laszlo and J Montoro and A Flechon and F Arpaci and S Secondino and P Wuchter and P Dreger and M Crysandt and N Worel and W Kruger and M Ringhoffer and A Unal and A Nagler and A Campos and A Wahlin and M Michieli and G Sucak and I Donnini and R Schots and N Ifrah and M Badoglio and M Martino and D Raggi and P Giannatempo and G Rosti and P Pedrazzoli and F Lanza",
year = "2016",
month = mar,
doi = "10.1038/bmt.2015.300",
language = "English",
volume = "51",
pages = "384--90",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party

AU - Necchi, A

AU - Miceli, R

AU - Bregni, M

AU - Bokemeyer, C

AU - Berger, L A

AU - Oechsle, K

AU - Schumacher, K

AU - Kanfer, E

AU - Bourhis, J H

AU - Massard, C

AU - Laszlo, D

AU - Montoro, J

AU - Flechon, A

AU - Arpaci, F

AU - Secondino, S

AU - Wuchter, P

AU - Dreger, P

AU - Crysandt, M

AU - Worel, N

AU - Kruger, W

AU - Ringhoffer, M

AU - Unal, A

AU - Nagler, A

AU - Campos, A

AU - Wahlin, A

AU - Michieli, M

AU - Sucak, G

AU - Donnini, I

AU - Schots, R

AU - Ifrah, N

AU - Badoglio, M

AU - Martino, M

AU - Raggi, D

AU - Giannatempo, P

AU - Rosti, G

AU - Pedrazzoli, P

AU - Lanza, F

PY - 2016/3

Y1 - 2016/3

N2 - Little is known about the prognostic impact of prior paclitaxel therapy and response to induction chemotherapy defined as the regimen preceding high-dose chemotherapy (HDCT) for the salvage therapy of advanced germ cell tumors. Twenty European Society for Blood and Marrow Transplantation centers contributed data on patients treated between 2002 and 2012. Paclitaxel used in either prior lines of therapy or in induction-mobilization regimens was considered. Multivariable Cox analyses of prespecified factors were undertaken on PFS and overall survival (OS). As of October 2013, data for 324 patients had been contributed to this study. One hundred and ninety-two patients (59.3%) had received paclitaxel. Sixty-one patients (19%) had a progression to induction chemotherapy, 234 (72%) a response (29 (9%) missing or granulocyte colony-stimulating factor without chemotherapy). Both progression to induction chemotherapy and prior paclitaxel were significantly associated with shorter OS univariably (P<0.001 and P=0.032). On multivariable analysis from the model with fully available data (N=216) progression to induction was significantly prognostic for PFS and OS (P=0.003), but prior paclitaxel was not (P=0.674 and P=0.739). These results were confirmed after multiple imputation of missing data. Progression to induction chemotherapy could be demonstrated as an independent prognostic factor, in contrast to prior paclitaxel.Bone Marrow Transplantation advance online publication, 7 December 2015; doi:10.1038/bmt.2015.300.

AB - Little is known about the prognostic impact of prior paclitaxel therapy and response to induction chemotherapy defined as the regimen preceding high-dose chemotherapy (HDCT) for the salvage therapy of advanced germ cell tumors. Twenty European Society for Blood and Marrow Transplantation centers contributed data on patients treated between 2002 and 2012. Paclitaxel used in either prior lines of therapy or in induction-mobilization regimens was considered. Multivariable Cox analyses of prespecified factors were undertaken on PFS and overall survival (OS). As of October 2013, data for 324 patients had been contributed to this study. One hundred and ninety-two patients (59.3%) had received paclitaxel. Sixty-one patients (19%) had a progression to induction chemotherapy, 234 (72%) a response (29 (9%) missing or granulocyte colony-stimulating factor without chemotherapy). Both progression to induction chemotherapy and prior paclitaxel were significantly associated with shorter OS univariably (P<0.001 and P=0.032). On multivariable analysis from the model with fully available data (N=216) progression to induction was significantly prognostic for PFS and OS (P=0.003), but prior paclitaxel was not (P=0.674 and P=0.739). These results were confirmed after multiple imputation of missing data. Progression to induction chemotherapy could be demonstrated as an independent prognostic factor, in contrast to prior paclitaxel.Bone Marrow Transplantation advance online publication, 7 December 2015; doi:10.1038/bmt.2015.300.

U2 - 10.1038/bmt.2015.300

DO - 10.1038/bmt.2015.300

M3 - SCORING: Journal article

C2 - 26642334

VL - 51

SP - 384

EP - 390

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 3

ER -